Professional Documents
Culture Documents
Kwan Et Al 2000 - Epilepsy After The First Drug Fails Substitution or Addon?
Kwan Et Al 2000 - Epilepsy After The First Drug Fails Substitution or Addon?
Kwan Et Al 2000 - Epilepsy After The First Drug Fails Substitution or Addon?
Epilepsy Unit, University Department of Medicine and Therapeutics, Western Infirmary, Glasgow,
Scotland, UK
Correspondence to: Professor M. J. Brodie, Epilepsy Unit, Department of Medicine and Therapeutics, Western
Infirmary, Glasgow G11 6NT, Scotland, UK. E-mail: Martin.J.Brodie@clinmed.gla.ac.uk
When and how a combination of antiepileptic drugs (AEDs) should be used in patients unresponsive to monotherapy is not
known. We followed up prospectively 248 patients in whom treatment with the first AED was unsuccessful. When treatment
failed due to intolerable adverse events, a second (substituted) drug was prescribed. When failure was due to lack of efficacy,
either AED substitution or combination (add-on) was undertaken. Patients were considered to be seizure-free if they had no
seizures for at least 1 year. Among patients with inadequate seizure control on the first well tolerated AED, those who received
substituted monotherapy (n = 35) and those who received add-on treatment (n = 42) had similar seizure-free rates (substitution
vs. add-on: 17% vs. 26%) and incidence of intolerable side effects (substitution vs. add-on: 26% vs. 12%). Based on the drugs’
perceived primary mode of action, more patients became seizure-free when the combination involved a sodium channel blocker
and a drug with multiple mechanisms of action (36%) compared to other combinations (7%, P = 0.05). None of the 11 patients
who received add-on treatment after a second drug had also failed became seizure-free, compared to 26% in those who received
add-on as soon as the first tolerated AED proved to be ineffective (n = 42, P = 0.05). These preliminary observations have
generated verifiable hypotheses regarding the early management of epilepsy. A randomized study comparing substitution and
combination after the failure of the first AED is underway.
c 2000 BEA Trading Ltd
Key words: epilepsy; antiepileptic drugs; outcome; monotherapy; polytherapy; mechanism of action.
470 190 65 25
100
Adverse events
18% 21%
29% 36%
80 Inadequate
seizure control
% patients
62%
40
47% 64%
20 35%
17%
0
1 2 3 4
Number of different antiepileptic drug regimens
Fig. 1: Response to successive antiepileptic drug regimens.
1997. No patients had received AED therapy prior Patients in whom the first AED was replaced by
to enrolment. Patients in whom treatment with the an alternative were analysed according to the reason
first AED was unsuccessful entered the study. The for substitution. In order to address the clinical ques-
choice of initial treatment took into account the type tion of appropriate treatment strategy for patients who
of seizures and epilepsy syndrome and other clini- experienced persistent seizures despite being able to
cal characteristics19, 21 . After commencement of med- tolerable the medication, we compared the response
ication, patients were reviewed at the epilepsy clinic to substitution and add-on therapy in those with in-
every 4–6 weeks for the first 6 months and at least adequate seizure control on the first well tolerated
every 4 months thereafter. A dedicated telephone line AED. AEDs were classified according to their pu-
was set up for the patients or their primary care tative primary mode of action17, 18 . Drugs that pri-
physicians to contact the Epilepsy Unit should prob- marily act on voltage-gated sodium channels include
lems arise between scheduled clinic appointments. carbamazepine, phenytoin and lamotrigine. Vigaba-
Compliance was monitored as necessary at the clinic trin and tiagabine enhance the inhibitory function
with the aid of on-site measurement of serum AED of γ -aminobutyric acid (GABA). Sodium valproate,
concentration22 . Dosages were titrated according to gabapentin and topiramate are classified as having
recommended schedules23, 24 and adjusted during multiple mechanisms of action. The chi-squared test
follow-up as clinical circumstances dictated paying and Fisher’s exact test were used for comparisons of
particular attention to efficacy and tolerability. Each categorical data. All statistical tests were two-tailed.
patient’s clinical information and response to treat- Calculations were made using Minitab for Windows
ment were recorded in a prospective database25 . (Release 11.21) software.
Response to medication was classified as seizure-
free (absence of any type of seizures or auras for at
least 1 year); failure of treatment due to inadequate RESULTS
seizure control despite ability to tolerate the med-
ication (lack of efficacy) or due to adverse events Among 470 previously untreated newly diagnosed
(including intolerable side effects and idiosyncratic re- patients referred to the clinic between 1 January 1984
actions); or withdrawal of treatment for reasons unre- and 31 December 1997, treatment with the first AED
lated to efficacy or tolerability such as concern about was unsuccessful in 248 patients (53%), who consti-
potential adverse events, planning a pregnancy, and a tuted the present study cohort. One hundred and thir-
change of mind. A change of drug regimen was de- teen patients had inadequate seizure control on the first
fined as either substitution by alternative monotherapy drug, 98 withdrew treatment due to adverse events (69,
or addition of another drug. Patients who developed intolerable side effects; 29, idiosyncratic reactions),
idiosyncratic reactions or intolerable side effects were and 37 due to other reasons2 . Fifty-two percent were
treated with an alternative drug (substitution). When male. The median follow-up period was 5 years (range
seizure control was inadequate, either substitution or 2–16 years). The median age at referral was 31 years
combination (add-on) was prescribed. (range 9–89 years), and the median age at onset of
466 P. Kwan & M. J. Brodie
100
14% Intolerable
19% 17% adverse events
29%
80 24%
Inadequate
% patients seizure control
60 45% Seizure-free
49%
20 38%
32%
16%
0
Inadequate Intolerable Idiosyncratic Other
control side effects reactions withdrawals
n = 31 n = 69 n = 29 n = 37
Fig. 2: Response to the second antiepileptic drug according to reason for failure of the first drug.
epilepsy was 28 years (range 1–87 years). A variety of AED combinations were employed
The percentage of successful treatment declined in (Table 1). Based on the drugs’ perceived primary
each successive drug regimen (monotherapy or combi- mechanisms of action, more patients became seizure-
nation), while that of patients with inadequate seizure free (Fig. 4) when the combination involved a sodium
control rose progressively (Fig. 1). Among the 248 channel blocker and an AED with multiple mecha-
patients whose epilepsy was not controlled on the nisms of action (36%) compared to other combina-
first AED, 166 received a substituted drug, 61 (37%) tions (7%, P < 0.05). None of the patients who re-
of whom became seizure-free on this second choice. ceived a combination of a sodium channel blocker and
Among the 113 patients with inadequate seizure con- a ‘pure’ GABA-ergic agent (vigabatrin or tiagabine)
trol on the first AED, 58 opted to continue on the became seizure-free.
same drug, 24 received add-on treatment, and 31 were
treated with a substituted drug, only five (16%) of
whom became seizure-free (Fig. 2, P < 0.01). Eigh- DISCUSSION
teen patients were not able to tolerate trials of two dif-
ferent AEDs, five patients three AEDs, and one was The argument against add-on therapy traditionally has
not able to tolerate even the fourth choice. been its propensity to cause greater toxicity without
When a tolerable AED was eventually identified, it substantial improvement in outcome11 . However, ad-
was still ineffective in 56 patients, 18 of whom then verse events due to pharmacokinetic and pharmaco-
received add-on treatment and four substitution, while dynamic interactions between AEDs can be equally
34 opted to continue on the same drug. Thus, among problematic during the substitution phase20, 26 . Only
all patients with inadequate seizure control on the 12% of our patients given combination therapy had
first tolerated AED, 42 (24 after the first drug and 18 to withdraw treatment due to side effects, which was
after subsequent drugs lacked efficacy) received add- a lower proportion, although not statistically signifi-
on therapy and 35 (31 after the first drug and four cantly so, than those who changed to a second drug
after subsequent drugs) received substitution. There (26%). Ninety percent of the combinations employed
was no significant difference in seizure-free rates (add- the newer drugs, some of which are better tolerated
on: 11 out of 42, 26%; substitution: 6 out of 35, 17%) than their older counterparts27, 28 .
or incidence of adverse events necessitating with- Although no significant difference in efficacy
drawal (add-on: 5 out of 42, 12%; substitution: 9 out was observed between alternative monotherapy and
of 35, 26%) between the two treatments (P = 0.25) duotherapy in our cohort, synergistic (supra-additive)
(Fig. 3). Eleven patients received add-on therapy at effects have been demonstrated for specific combi-
a later stage after the substituted drug failed to con- nations in comparative studies, notably sodium val-
trol the seizures. None of them became seizure-free, proate and lamotrigine20, 29 . This discrepancy is likely
compared to a seizure-free rate of 26% among those to be due to the inclusion of a relatively small number
who received add-on as soon as the first tolerated AED of patients taking a large number of different com-
failed (n = 42; P = 0.05). binations in the present study. Indeed, when the var-
Epilepsy after the first drug fails 467
40
*
100 * P < 0.05
Intolerable
12% adverse events
26% 30
Inadequate
80 seizure control
Seizure-free
% patients
60
% patients
62%
20
57%
40
20 10
26%
17%
0
Add-on Substitution
n = 42 n = 35 0
Sodium blocker + Other
multiple actions combinations
Fig. 3: Response to add-on or substitution in patients with in-
adequate seizure control on the first well tolerated antiepilep- n = 28 n = 14
tic drug.
Fig. 4: Response to different combinations of antiepileptic
drugs according to mechanisms of action.
Table 1: Combinations of antiepileptic drugs prescribed to Combination therapy was more effective when pre-
patients receiving add-on therapy with inadequate seizure
control on first well tolerated drug.
scribed immediately after the first drug failed due to
lack of efficacy than when it was delayed until treat-
No. of ment with a substitution also proved unsuccessful.
Combinations patients
This difference in efficacy might reflect the severity
Sodium channel blocker + multiple actions 28 of the underlying disease, i.e. patients unresponsive
LTG + VPA 12 to two successive AEDs might have more ‘drug re-
CBZ + GBP 6
CBZ + TPM 3 sistant’ epilepsy than those uncontrolled on just one
CBZ + VPA 2 drug. Whether pharmacoresistance is present de novo
LTG + TPM 3 or evolves over time is debatable2 . The concept of
LTG + GBP 1 seizures begetting seizures was first hypothesized by
PHT + VPA 1
Gowers30 in the last century and is supported by the
Two sodium channel blockers 5 experimental model of kindling, whereby electrical
CBZ + LTG 3
CBZ + PHT 1 stimulation at what is initially a subconvulsive level in
PHT + OXC 1 an animal subsequently becomes sufficient to induce
Sodium channel blocker + GABA-ergic drug 5 seizures after repeated application31 .
CBZ + VGB 2 Although clinical data in favour of the kindling hy-
LTG + VGB 2 pothesis in human epilepsy is lacking32 , there is good
CBZ + TGB 1 evidence to suggest that recurrent seizures, particu-
Two drugs with multiple actions 2 larly those involving the limbic structures, can cause
VPA + TPM 1 enduring disturbances in neuronal function33–35 . In
VPA + GBP 1
addition, long-term outcome studies of patients who
GABA-ergic + multiple actions 1 underwent temporal lobectomy for refractory tempo-
VGB + VPA 1
ral lobe epilepsy suggest that secondary epileptoge-
Sodium channel blocker + glutamate antagonist 1 nesis at sites distant to the lesion may develop with
PHT + REM 1
uncontrolled seizures36 . The self-perpetuating nature
Total 42 of seizures in some patients may account for the pro-
CBZ = carbamazepine; GBP = gabapentin; LTG = lamotrigine; gressive decline in the likelihood of seizure freedom
OXC = oxcarbazepine; PHT = phenytoin; REM = remacemide; achieved with successive treatment regimens.
TGB = tiagabine; TPM = topiramate; VGB = vigabatrin; VPA =
Findings from this observational study have rele-
sodium valproate; GABA = γ -aminobutyric acid.
vance to the formulation of a more strategic approach
in managing patients with newly diagnosed epilepsy.
ious combinations were grouped together according to When the first AED failed due to lack of efficacy, the
the AEDs’ primary mode of action, significantly more successful rate of an alternative monotherapy was only
patients given a sodium channel blocker and a drug 16%, compared to 47% in drug-naı̈ve patients. The
with multiple mechanisms became seizure-free than chance of seizure freedom with pharmacological treat-
those treated with other combinations. ment after failure of two consecutive AEDs due to in-
468 P. Kwan & M. J. Brodie